Magnetic Resonance Imaging (MRI) Safety Information

This device is labeled as MR Conditional. This means that the device has a demonstrated safety in a specified MRI environment with the defined conditions of use listed. The information on this page provides only a summary of MR conditions and is intended as a reference for the U.S. only. For a full version of conditions, please see product Instructions for Use (IFU).

The information on this page is current as of February 2024. For the most current and complete MR safety information on any product, always refer to the IFU.

GORE® TIGRIS® Vascular Stent (Product has been discontinued)

MR statusMR Conditional
Static magnetic field strengths1.5 tesla or 3.0 tesla
Maximum spatial gradient4000 gauss/cm
Max whole-body-averaged specific absorption rate (SAR)4.0 W/kg
Scan duration15 minutes of scanning
Image artifact (3 tesla, gradient echo pulse sequence)The image artifact extends approximately 5 mm from the device, both inside and outside the device lumen.
Time (post-implant) to safely scanNo restrictions listed in IFU

Consult Instruction for Use

INDICATIONS FOR USE: The GORE® TIGRIS® Vascular Stent is intended to improve luminal diameter in patients with symptomatic de-novo or restenotic lesions or occlusions in the native superficial femoral artery (SFA) and proximal popliteal artery (PPA) with reference vessel diameters ranging from 4.0 - 6.5 mm and lesion lengths up to 240 mm. 
CONTRAINDICATIONS: The GORE® TIGRIS® Vascular Stent is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. The GORE® TIGRIS® Vascular Stent is contraindicated in patients with contraindication to antiplatelet and/or anticoagulation therapy. DO NOT use the GORE® TIGRIS® Vascular Stent in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.
Refer to Instructions for Use for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

Product has been discontinued and is not available in any market.

231313850-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.